Biosenic SA

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

08 Jan 2024 11:00:00 By Nasdaq GlobeNewswire

ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

08 Dec 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

06 Dec 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic provides third quarter 2023 Business Update

25 Oct 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024

18 Oct 2023 00:00:00 By Nasdaq GlobeNewswire

Correction: BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS

17 Oct 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

27 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis

19 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts

14 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic reports half year 2023 results

07 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

01 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases

24 Aug 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

03 Aug 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic provides further update on negotiations with its main creditors

10 Jul 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

03 Jul 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic provides financial update

30 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine

20 Jun 2023 04:31:14 By Nasdaq GlobeNewswire

BioSenic puts Phase IIb ALLOB trial on hold

19 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

01 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

BioSenic provides update regarding current license agreement with Phebra

29 May 2023 00:00:00 By Nasdaq GlobeNewswire